BioSpace News Archive

The Pamoja Tulinde Maisha (PALM, Kiswahili for “together save lives”) trial, a large Ebola research effort supported by the Frederick National Laboratory, has received the David Sackett Trial of the Year Award for 2019.

Tissue obtained from tumors during an autopsy conducted shortly after a cancer patient’s death provides unique insights into how the tumors evolved, spread and resisted treatment. The Frederick National Laboratory’s Molecular Characterization Laboratory reports on results of a study on preclinical models established from “rapid autopsy” tumors during the 2020 American Society for Clinical Oncology Virtual Scientific Program, May 29-31.

The National Lipid Association (NLA) today announced the release of its official scientific statement on the use of genetic testing in the diagnosis and management of patients with dyslipidemia. The statement provides insights and guidance for health care providers seeking to further their understanding of the benefits, risks and patient preferences of genetic testing. “While next-generation DNA sequencing tests are becoming more accessib

Three employees from Frederick National Laboratory’s Imaging and Visualization Group recently claimed a top spot of a computing and artificial intelligence challenge that attracted 170 competing groups from around the world.

BioSig Technologies, Inc., a medical technology company commercializing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, announced that the Company has submitted its application to Systems for Award Management.

Adamas Pharmaceuticals, Inc. announced that the compensation committee of the company’s board of directors granted three new employees the option to purchase an aggregate of 62,500 shares of the company’s common stock, at a per share exercise price of $2.57, the closing trading price on July 8, and restricted stock units to acquire 31,250 shares of the company’s common stock.

Mirum Pharmaceuticals, Inc. announced that the Compensation Committee of Mirum’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 70,900 shares of common stock to four new employees under Mirum’s 2020 Inducement Plan.

Lincoln International is pleased to announce that The Araz Group, Inc. (d/b/a HealthEZ), a leading independent third-party administrator (TPA) of self-funded medical plans, has received an investment from Abry Partners LP, a private investment firm focused on investing in and building market-leading middle market businesses

Regulatory News: Under the liquidity contract entrusted by Median Technologies (Paris:ALMDT) (FR0011049824 – ALMDT FP) to Louis Capital Markets UK LLP, the following resources were listed in the liquidity account as of June 30, 2020: 32,518 shares €77,124.37 in cash Transactions during the first half 2020: BUY 114,265 shares 455,351.48 EUR

Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (“Qualigen” or the “Company”), today announced the closing of its previously announced registered direct offering, priced at-the-market under Nasdaq rules, with a single institutional investor for the purchase and sale for $8,000,000 of (i) 1,140,570 shares of Common Shares,